Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan
Phase 2
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03020095
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 141
- Registration Number
- NCT03020082
Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03020134
Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03019991
© Copyright 2025. All Rights Reserved by MedPath